アピキサバンとアスピリンは,暗号性脳卒中と心房不全後の認知低下を軽減する:ARCADIA-認知研究

Ronald M Lazar¹, George Howard², Michael T Brewer¹

¹UAB McKnight Institute, Department of Neurology, UAB Heersink School of Medicine University of Alabama at Birmingham Birmingham AL USA.

Journal of the American Heart Association

|August 23, 2025

まとめ

アピキサバンは,暗号性脳卒中後の心房不全の患者で,アスピリンと比較して,より遅い認知低下を示さなかった. この集団における認知障害の最適な治療法を見つけるにはさらなる研究が必要である.

科学分野:

神経科学
心臓病科
薬理学について

背景:

アピキサバとアスピリンの二次性脳卒中予防を研究したARCADIA研究では,心房内疾患の患者で
研究は無益で早期に終了した.
ARCADIA- Cognition研究は,これらの治療が認知機能低下に与える影響を評価することを目的とした.

研究の目的:

暗号性脳卒中後の患者におけるアピキサバンとアスピリンの認知低下の軌道を比較する.
マイクロエンボリゼーションの減少により認知機能の低下が遅くなるという仮説を評価する.

主な方法:

認知機能は電話による標準テストで評価された.
5つの認知テストのZスコアを組み合わせて認知能力を測定した.
アピキサバンとアスピリン群の認知経路を比較するために,混合効果モデルを使用した.

主要な成果:

最初の分析には合計249人の患者 (128人がアピキサバン,121人がアスピリン) が含まれていた.
アピキサバン (0. 107) とアスピリン (0. 084) の両腕 (P=0. 62) の複合認知Zスコアの年次変化には有意な違いは認められなかった.
2つの治療群の認知経路は有意に違わなかった.

結論:

アピキサバンとアスピリンは,暗号性脳卒中後の心房不全の患者に異なる認知経路をもたらさなかった.
将来の研究では,この患者群の認知機能低下に対する治療法を最適化するために,心臓発作の特徴と並行病理を調査する必要があります.

キーワード:

アピキサバンアスピリン心房内疾患認知能力隠された心臓発作

さらに関連する動画

28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

33.5K

07:30

Evaluation of the Cognitive Performance of Hypertensive Patients with Silent Cerebrovascular Lesions

Published on: April 23, 2021

3.1K

関連する概念動画

01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

1.3K

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

1.3K

01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

893

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

893

01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

645

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

645

01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...

関連する実験動画